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Abstract: Alzheimer’s disease (AD) is diagnosed using neuropsychological testing, supported by
amyloid and tau biomarkers and neuroimaging abnormalities. The cause of neuropsychological
changes is not clear since they do not correlate with biomarkers. This study investigated if changes
in cellular metabolism in AD correlate with neuropsychological changes. Fibroblasts were taken
from 10 AD patients and 10 controls. Metabolic assessment included measuring total cellular
ATP, extracellular lactate, mitochondrial membrane potential (MMP), mitochondrial respiration
and glycolytic function. All participants were assessed with neuropsychological testing and brain
structural MRI. AD patients had significantly lower scores in delayed and immediate recall, semantic
memory, phonemic fluency and Mini Mental State Examination (MMSE). AD patients also had
significantly smaller left hippocampal, left parietal, right parietal and anterior medial prefrontal
cortical grey matter volumes. Fibroblast MMP, mitochondrial spare respiratory capacity (MSRC),
glycolytic reserve, and extracellular lactate were found to be lower in AD patients. MSRC/MMP
correlated significantly with semantic memory, immediate and delayed episodic recall. Correlations
between MSRC and delayed episodic recall remained significant after controlling for age, education
and brain reserve. Grey matter volumes did not correlate with MRSC/MMP. AD fibroblast metabolic
assessment may represent an emergent disease biomarker of AD.
Keywords: Alzheimer’s disease; mitochondrial spare respiratory capacity; mitochondrial;
membrane potential; glycolytic reserve; semantic memory; phonemic fluency; episodic memory;
neuropsychology; neuroimaging
1. Background
Alzheimer’s disease (AD) is the most common cause of dementia worldwide and in 2018 was
estimated to cost the global economy 1 trillion US dollars [1]. The clinical symptoms of the disease
are the progressive loss of different aspects of cognitive function until a patient becomes completely
dependent on the care of family members and healthcare workers [2]. Median survival after diagnosis
is 7 to 10 years for people in their 60s to 70s, and 3 years for people in their 90s [3].
The disease is characterized pathologically by the presence of extracellular amyloid plaques
comprising mainly of the amyloid beta protein; and intracellular neurofibrillary tangles (NFT) made
mainly of the cytoskeletal protein tau [4]. To date the cause of AD still remains poorly understood.
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As the buildup of amyloid appears to be a key step in the development of both familial and sporadic
forms of the disease, the amyloid cascade hypothesis has become the leading theory for the cause of
the condition [5]. In brief, this hypothesis states that the key step in developing AD is the accumulation
of amyloid beta through reduced breakdown and clearance, and/or increased production. Strategies
aimed at reducing the amyloid load in the brain, however, have failed to control the disease [6] and have
resulted in a large number of clinical trials that have failed to achieve primary outcome measures [7].
Even in pre-clinical carriers of dominantly inherited AD mutations, amyloid removal therapies have
not slowed disease progression [8]. Furthermore, brain amyloid load does not correlate with clinical
symptoms [9]. This has led researchers to investigate alternative pathophysiological mechanisms [10].
AD is clinically defined by distinctive changes in cognitive status identified by neuropsychological
assessment. Brain imaging changes and amyloid and tau protein levels in the cerebrospinal fluid are
used to confirm the diagnosis in vivo [11]. The changes seen in a patient’s ability to perform a cognitive
task are often difficult to explain from a cellular perspective. Tau deposition does explain elements
of the observed neuropsychological abnormalities [12], but does not fully account for all cognitive
changes observed in AD patients [13,14].
Cognitive processing, such as that required while performing memory tasks, puts an increased
metabolic demand on the brain [15]. This is evidenced by neuroimaging studies of the brain which
use tracers of metabolism such as 2-[18F]fluoro-2-Deoxy-D-glucose (FDG) that have shown poor
glucose utilization in patients who perform poorly on memory tasks [16,17]. Positron-emission
tomography (PET) imaging studies that use oxygen-15 labelled water also show reduced uptake when
AD patients perform cognitive tasks [18]. These imaging studies suggest that any deficit in metabolic
function, such as deficits in mitochondrial respiration or glycolysis, are likely to affect an individual’s
performance on cognitive tasks. It is therefore possible that mitochondrial respiration or glycolytic
dysfunction might contribute to cognitive deficits in AD, making these cellular processes suitable
pharmacological targets to improve the cognitive symptoms of AD.
Cellularmetabolic changeswithin the brains of patients withAD and in peripheral cell populations
are seen very early in the condition, and often precede the development of both amyloid plaques and
NFT. Abnormalities have been shown in many metabolic pathways in AD [19]. Mounting evidence
suggests that deficits in glycolysis and the function of mitochondria, specifically how they control
oxidative phosphorylation, are likely to be key in the development and establishment of AD [20–22].
A mitochondrial cascade hypothesis has been suggested for the aetiology of AD, and states that
people who inherit mitochondrial genes that predispose them to lower mitochondrial respiration rates
may be more likely to develop the condition [23]. In animal models of AD, changes in mitochondrial
function are seen prior to amyloid deposition [20,24], and cell models show changes in mitochondrial
function and oxidative stress without the presence of amyloid [25], giving further evidence for the key
role of mitochondrial dysfunction in AD.
Impairment of glycolysis is also seen early in patients with AD. A 2-[18F]fluoro-2-Deoxy-D-glucose
positron-emission tomography (FDG-PET) imaging of the brain shows a reduction in glucose
metabolism [26]. In particular, there is a reduction in aerobic glycolysis in brain areas susceptible to
amyloid deposition [27], and in those regions where high levels of tau accumulation are seen [28].
We have previously shown that fibroblasts from sporadic AD (sAD) patients have multiple
mitochondrial structural and functional abnormalities, and that these can be ameliorated by treatment
with ursodeoxycholic acid (UDCA) [29]. Other studies have shown that glycyl-l-histidyl-l-lysine
(GHK-Cu), by increasing gene expression, has an effect on improving mitochondrial activity and
influencing cognitive decline [30]. In our previous study we showed sAD fibroblasts to have deficits in
mitochondrialmembranepotential (MMP) andmitochondrial spare respiratory capacity (MSRC).MSRC
refers to the difference in oxidative phosphorylation rates between the basal level of mitochondrial
respiration and the maximal level a cell can achieve [31]. In essence, MSRC measures the cellular
reserve respiratory capacity. In animal models of AD it has been shown that deficits in MSRC cause
cognitive deficits that treatment with the antioxidant pyrroloquinoline quinone can improve [32]. It has
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not been previously shown, however, whether changes in MSRC in human cell lines obtained from
sAD patients correlate with their performance on neuropsychological tests.
As deficits in both glycolysis and mitochondrial function have been shown in AD patients and
models, in this proof of concept study we explored metabolic function in fibroblasts from sporadic AD
patients and its role in the cognitive decline experienced by these patients. To this end, we assessed
mitochondrial functional changes in a larger cohort of patients compared to the findings described in
our previous study [29]. We have then assessed additional metabolic parameters in the sAD fibroblasts
including glycolytic function and cellular ATP levels, which have previously not been described.
Finally, we investigated whether these metabolic abnormalities detected in sAD fibroblasts correlated
with neuropsychological and neuroimaging features typical of the early stages of this disease.
2. Results
2.1. Patient Demographic Details
Skin biopsies were taken from ten sAD patients (mean age 61.3 years, 6 male) and ten controls
(mean age 66.7 years, 5 male). Body mass index (BMI) did not differ significantly between the groups
(sAD mean 27.8 kg/m2 SD 5.37 kg/m2 Controls mean 28.2 kg/m2 SD 4.00 kg/m2 t-test p = 0.44). Table 1
shows patient and control demographic data.
Table 1. Patient Demographic Information and contemporary treatment status.
Patient Number Age (Years) Sex MMSE
Length of
Education (Years)
AD Treatment (in Disease Cohort,
at Time of Biopsy)
1 63 Male 20 16 None
2 57 Male 18 15 Donepezil
3 53 Male 14 11 Donepezil
4 * 60 Male 18 9 None
5 * 59 Female 23 11 Galantamine
6 * 63 Female 26 10 Donepezil
7 * 60 Male 18 11 Memantine
8 60 Male 18 11 None
9 79 Female 28 15 None
10 61 Female 25 11 Donepezil
Group Mean
(Standard Dev)
61.33
(7.19)
20.8
(4.4)
12.0
(2.4)
Controls
1 66 Male 29 11 NA
2 * 54 Male 27 17 NA
3 * 53 Male 29 16 NA
4 * 56 Male 24 11 NA
5 61 Female 30 NA NA
6 54 Female 29 17 NA
7 * 100 Female 24 # 14 NA
8 75 Female 28 18 NA
9 73 Female 26 12 NA
10 75 Male 27 10 NA
Group Mean
(Standard Dev)
65.77
(14.7)
27.6
(1.8)
14
(3.1)
# For control 7 some items of the Mini Mental State Examination (MMSE) could not be tested due to sensory
impairment * indicates fibroblast lines in which Mitochondrial Membrane Potential (MMP) and Mitochondrial
Spare Respiratory Capacity (MRSC) values were published in our previous paper [29].
2.2. Neuropsychological Profiles
Neuropsychological profiling of controls and patients used in this study was performed as part
of the VPH-DARE research project (http://www.vph-dare.eu/), (see Methods section for additional
details). For the present study, a subgroup of neuropsychological tests was selected to be correlated
with metabolic findings. The tests which can detect the earliest typical cognitive impairments in mild
sAD were selected. These included assessment of semantic memory, immediate and delayed episodic
recall. Phonemic fluency was also selected as dysfunction on this cognitive test is seen later in AD but
not in its earlier stages [33]. All 10 controls and 10 patients with AD were assessed. The Mini-Mental
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State Examination (MMSE) [34] was also used, as this test is useful in staging disease severity in
sAD [34,35].
Patients with sAD performed at a lower level than controls on all tests (see Figure 1). The most
significant differences were seen in the tests of semantic memory (mean score in controls 42.6 points,
mean score in sAD 17.5 points, difference between means 25.1 points, SD 4.774 p < 0.0001); immediate
(mean score in controls 15.8 points, mean score in sAD 6.4 points, difference between means 25.1
points, SD 1.468 p < 0.0001); and delayed recall of the Prose Memory test (mean score in controls 18.6
points, mean score in sAD 5.5 points, difference between means 13.4 points, SD 1.488 p < 0.0001).
The phonemic fluency test performance was also significantly different between the 2 groups (mean
score in controls 50.5 points, mean score in sAD 27.4 points, difference between means 23.1 points, SD
6.837 p = 0.0033), but to a lesser extent than the other neuropsychological tests. As expected, MMSE
scores of sAD patients were significantly lower than those of controls (mean score in controls 27.3
points, mean score in sAD 21.3 points, mean difference 6.0 points, SD 1.54 p = 0.0011).

 ?
&RQ
WURO V$'







,PPHGLDWH(SLVRGLF5HFDOO
,P
PH
GLD
WH
5H
FDO
O6
FRU
H 
&RQ
WURO V$'







'HOD\HG(SLVRGLF5HFDOO

&RQ
WURO V$'





6HPDQWLF0HPRU\

&RQ
WURO V$'






3KRQHPLF)OXHQF\

&RQ
WURO
V V$'





 
0LQL0HQWDO6WDWH([DPLQDWLRQ
$ %
'&
(
Figure 1. Mean scores of sporadic AD (sAD) patients and controls on cognitive tests included in the
neuropsychological assessment. Graphs show mean with error bars indicating standard deviation.
**** p < 0.0001; *** p < 0.001; ** p < 0.01. Controls are indicated by blue bars and sAD patients indicated
by green bars. Significant reductions were seen in sAD immediate recall (A), delayed recall (B), semantic
memory (C), phonemic fluency (D) and Mini Mental State Examination (E) when compared to controls.
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2.3. Neuroimaging Profiles
Volumetric structural MRI scans were acquired on 9 controls and 10 patients with sAD. One
control did not complete their MRI scan as an incidental finding (of no diagnostic significance for this
study) on initial scans meant the participant could no longer take part in the VPH-DARE@IT original
study. For the remaining participants, the left and right parietal lobes, anterior medial pre-frontal
cortex and posterior cingulate gyrus, and left hippocampal grey matter volumes were extracted as
these brain areas are affected early in AD [36].
Comparisons between the 2 groups showed no significant differences between the grey matter
volumes of the preselected areas when performing a t-test. Brain grey matter volumes can be affected
by age, education and brain reserve [37,38]. For these reasons a further analysis of the 2 groups was
completed controlling for these covariates. A significant difference emerged in the volume of the
left hippocampus, left parietal, right parietal and anterior medial prefrontal cortex in patients with
sAD after controlling for confounding variables. Table 2 highlights the F-test and p-values for these
differences. No significant difference was seen in the posterior cingulate cortex grey matter volume
between the 2 groups.
Table 2. Differences in Control and sAD brain volumes. This table shows the significance of the
differences in brain volumes between controls and patients with sAD when controlling for age, years of
education and brain reserve.
Brain Volume F-Test p-Value
Left Hippocampal Volume 9.420 0.001
Left Parietal Volume 7.882 0.002
Right Parietal Volume 10.051 <0.0001
Anterior Medial Prefrontal Cortex 0.056 0.017
Posterior Cingulate Cortex 0.752 0.575
2.4. Fibroblast Metabolic Assessment
Mitochondrial function was investigated in both sAD patients and controls. We measured
elements of both mitochondrial function and glycolysis. Five metabolic parameters were chosen that
best describe different factors influencing the ability of the fibroblast to meet its energy demands.
Mitochondrial parameters included: total cellular ATP, as this is a global marker of the energetic status
of the cell; MMP and MSRC. MMP and MSRC were selected as these parameters are important in
maintaining the rate of ATP production as cellular energy demand changes. These are also the two
parameters which we have previously identified as being relevant to the mitochondrial phenotype in
sAD fibroblasts [29]. Measures of glycolysis included glycolytic reserve and extracellular lactate levels.
Glycolytic reserve, like MSRC and MMP for mitochondrial function, is a measure of cellular metabolic
flexibility and deficits in this parameter are likely to contribute to an inability to maintain cellular
energy production. Extracellular lactate is the final breakdown product of glycolysis and contributes
information about how well the cell can utilize glucose as a metabolite.
First, we assessed MMP and MRSC as we have done in our previous work [29]. In this cohort,
MRSC was significantly reduced (36% reduction p < 0.0001) in sAD when compared to controls
(Figure 2A). MMP was also significantly reduced in the sAD fibroblast lines (14% reduction p = 0.011)
(See Figure 2B). Figure 2C shows a representative oxygen consumption trace for the mitochondrial
stress test experiment.
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Figure 2. Oxidative phosphorylation and Glycolytic fibroblast Assessment: *** = p < 0.001; * = p < 0.05.
Significant reductions in mitochondrial spare respiratory capacity (A), Mitochondrial Membrane
potential (D), Glycolytic Reserve (E) and Extracellular lactate (G) was detected in sAD when compared
to controls. No significant difference was seen in total cellular ATP (B). OCR and ECAR traces for
mitochondrial stress test and glycolysis stress test are displayed in panels (C) and (F) respectively.
For all panels controls are represented in blue and sAD are represented in green. Graphs represent
mean with error bars indicating standard deviation.
Next, we assessed total cellular ATP, which showed no significant difference between sAD patient
fibroblasts and controls when comparing mean values (p = 0.165, Figure 2D). The final metabolic
assessment of the fibroblast lines involved assessment of glucose metabolism using the glycolysis
stress test programme on the Seahorse analyzer and extracellular lactate measurement. A significantly
lower glycolytic reserve was found in sAD fibroblasts when compared to controls (see Figure 1E, 25.8%
reduction, p = 0.031). No significant differences were seen in maximum glycolytic rate (p = 0.792),
or basal glycolytic rate (p = 0.381). Figure 1F shows the extracellular acidification rate (ECAR) trace
for the glycolysis stress test, comparing the group of controls against the sAD fibroblast group.
Measurement of extracellular lactate levels revealed significantly lower lactate levels released from
sAD fibroblasts (14% reduction, p = 0.0227, Figure 2G).
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2.5. Neuropsychological/Metabolic Correlations
Next, we sought to correlate the neuropsychological scores of the sAD patients and controls
combined with their metabolic parameters measured in fibroblasts. As five neuropsychological
measures and five fibroblast metabolic markers had been assessed to identify differences in the control
and sAD fibroblast groups, we controlled for the effect of multiple comparisons by adjusting what we
deemed to be a significant association to p ≤ 0.01 (0.05/5). Using this new statistical threshold, only
MSRC and MMP metabolic tests and immediate, delayed and semantic memory neuropsychological
assessments were identified as significantly different between control and sAD groups. Correlations
were, therefore, performed only for these data sets.
MSRC had a significant positive correlation with immediate episodic recall (r = 0.612, p = 0.004),
delayed episodic recall (r = 0.669, p = 0.001) and semantic memory scores (r = 0.614, p = 0.003).
MMP correlated only with semantic memory scores (r = 0.565, p = 0.009). Immediate episodic recall
(r = 0.552, p = 0.0134) and delayed episodic recall correlated positively with MMP, but at a lower level
of significance (r = 0.540, p = 0.015). Figure 3 displays these correlations graphically.
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Figure 3. Neuropsychological Fibroblast Metabolism Correlations. Significant correlations were seen
between mitochondrial spare respiratory capacity (MSRC) and delayed recall (A), Immediate recall
(B) and semantic fluency (C). Mitochondrial membrane potential (MMP) correlated significantly with
semantic fluency (F), and with delayed recall (D) and immediate recall (E) but to a lesser extent. For all
panels controls are represented in blue and sAD are represented in green. Correlation coefficients and
p-values for each correlation are displayed.
Age, years of education and brain reserve can potentially confound the correlations between
neuropsychological measurements and the fibroblast metabolic markers, as all three factors have been
shown to affect either performance onneuropsychological tests [39,40] ormitochondrial function [41]. To
control for the effect of these three covariates, a further analysis was performed taking these parameters
into account. This further analysis showed that the correlation between delayed episodic recall and
MSRC was still significant at the more conservative significance threshold. Both immediate episodic
recall (p = 0.013) and semantic memory (p = 0.012) correlations with MSRC were no longer significant
once covariates were included in the analysis at the new more stringent p-value. All correlations seen
between the neuropsychological tests and MMP were no longer significant after controlling for age,
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education and brain reserve. Table 3 displays the new correlation coefficients and p-values for the
neuropsychological data.
Table 3. Neuropsychological fibroblast metabolism correlations corrected for age, years of education
and grey matter reserve.
Psychological Test Fibroblast Marker R Value p-Value
Immediate Episodic Recall
MSRC 0.605 0.013
MMP 0.196 0.466
Delayed Episodic Recall
MSRC 0.695 0.003
MMP 0.204 0.448
Semantic Memory
MSRC 0.610 0.012
MMP 0.345 0.191
2.6. Neuroimaging/Metabolic Correlations
Volumetric imaging for areas of the brain known to be affected by AD were correlated with
metabolic markers of the disease. Only the grey matter volumes that had shown significant differences
between the sAD and control groups (with a p-value equal to or less than 0.01) were included. None of
the grey matter volumes showed a significant correlation with changes in cellular metabolism. Table 4
shows the results of the correlations.
Table 4. Grey Matter Volume Fibroblast metabolic correlations: No significant correlations were seen
between MMP nor MSRC and any grey matter volume when controlling for age, length of disease or
brain reserve.
Grey Matter Volume Fibroblast Marker R Value p-Value
Left Hippocampal Volume
MSRC 0.371 0.157
MMP 0.041 0.881
Left Parietal Volume
MSRC 0.341 0.196
MMP −0.047 0.862
Right Parietal Volume
MSRC 0.418 0.107
MMP −0.043 0.875
3. Discussion
This proof of concept study shows that fibroblast MSRC correlates with established
neuropsychological abnormalities that are affected early in AD. This is one of the first studies
to show a functional biomarker of AD correlating with a marker of fibroblast mitochondrial function.
MSRC is a measure of the ability of mitochondria within cells to increase the production of ATP in
response to an increased energy demand. The correlation of MSRC with neuropsychological scores
potentially helps to describe the cellular pathology underlying these neuropsychological changes
seen in AD. This is the first study in humans to show that peripheral cell MSRC correlates with
neuropsychological profiles. Correcting the abnormality in MSRC could be a future therapeutic
approach in AD. The fact that this abnormality in mitochondrial function correlates with a clinical
biomarker of AD also opens the avenue for monitoring drug response in future clinical trials.
MSRC has been shown to be abnormal in multiple diseases including acute myeloid leukaemia
(AML) [42], Parkinson’s disease [43,44] and motor neuron disease (MND) [45]. MSRC deficits may
not be disease specific, but the combination of cellular metabolic changes seen here may represent
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a cellular metabolic profile specific to sAD. This metabolic phenotype could potentially represent a
biomarker that can stratify and define a specific subset of sAD patients that might then respond to a
personalised therapeutic approach. Previous research has shown that the metabolic profile identified
in fibroblasts from sporadic Parkinson’s disease patients differs from that identified here in fibroblasts
from sAD [46,47].
Reductions in MSRC and MMP were seen in all sAD fibroblast lines when compared to controls
at a group level. These data reinforce and extend the findings reported in our previous paper [29], and
show that the finding of reduced MSRC and MMP is reproducible and more robust in sporadic AD
fibroblasts when sample size is increased. Extracellular lactate levels and cellular glycolytic reserves,
both markers of glycolytic function, were significantly reduced in all sAD fibroblasts. These measures,
however, did not meet the statistical significance for correlation with neuropsychological markers of
the disease. The deficits in markers of mitochondrial function and glycolysis in the fibroblasts reflect a
lack of flexibility of metabolic pathways in sAD. This lack of flexibility is likely to be very important
when performing cognitive tasks that depend on the coordination of multiple brain regions. Taken
together, these results suggest that sAD fibroblasts may have limited ability to respond to increased
cellular energy demand.
MMP did correlate with neuropsychological markers, but correlations did not survive the
correction for confounding factors unlike MSRC, for which correlation with delayed episodic recall
(a core feature in the clinical diagnostic criteria for sAD) remained significant. Semantic memory
and immediate episodic memory did not significantly correlate with MSRC at the more conservative
significance threshold after confounder consideration, but p-values for both of these correlations were
less than 0.02. Potentially, these correlations would reach significance level with an increased sample
size. The difference in MMP between control and sAD groups was much smaller than the difference
seen in MSRC. MMP has a key role in maintaining many pathways in the mitochondria outside that of
ATP generation, such as apoptosis fates [48]. It is likely that several mechanisms not affected by sAD
in the fibroblast cell help to maintain MMP levels, which may explain the reduced variability seen in
this parameter in sAD and the lack of a significant correlation with neuropsychological scores.
Baseline ATP levels were not significantly different between the two groups. These results
suggest that, in a controlled environment when cells are not stressed, they can maintain ATP levels
similar to that of controls. Interestingly though, the functional capacity of mitochondria is impaired,
as described above, suggesting a potential inability to respond appropriately to increased ATP demand.
The measurements of ATP we performed in this study only gives information about the total cellular
ATP level. We did not investigate the rate of ATP breakdown nor how ATP levels change when
the cell is under stressed conditions or the ratio of ATP/ADP in the cell. This may explain why no
significant correlations were seen with ATP measurements, but were seen with the other markers of
mitochondrial respiration.
It is interesting that the correlation between scores on phonemic fluency, a neuropsychological
test not affected early in sAD, and cell metabolism markers did not reach significance threshold. It.
The medial temporal lobe is important in semantic memory processing [49], an area of cognition that
is impaired very early in sAD [50]. This is not the case for phonemic fluency which is supported
by processes associated with frontal executive regions [51]. It could be that the correlations we see
between neuropsychological tests and cellular metabolic function may reflect which areas of the brain
are more susceptible to metabolic failure. It has been previously shown that areas of the brain that are
affected early in sAD express lower levels of electron transport chain (ETC) genes when compared
to controls [52], suggesting that this might be the case. Data from FDG-PET studies also support
the concept of focal brain hypometabolism in sAD, with areas such as the medial temporal lobes,
precuneus and lateral parietal lobes all preferentially affected [53].
We did not see a significant correlation between mitochondrial function or glycolysis and brain
structural imaging markers of sAD. This may be explained by the fact that multiple factors can affect
grey matter volume such as age, levels of education and brain reserve. It has been previously shown
J. Pers. Med. 2020, 10, 32 10 of 16
that smaller grey matter volumes in the frontal lobes associated with ageing are associated with worse
performance on frontal lobe cognitive tests [54]. The neuropsychological assessment performed in this
study mainly focused on temporal lobe cognitive functioning and not frontal lobe function. Potentially,
the effect of brain ageing on grey matter volumes may mask any effect metabolic function may have.
The limitations of our study include a small sample size, and the fact that we have used fibroblasts
to measure metabolic function. It could also be argued that a correlation between metabolic function of
central nervous system cells and neuropsychological parameters would be more meaningful. This is
not the first study, however, to show that the metabolism of peripheral cells outside the nervous
system is affected in sAD. White blood cells [55], platelets [56] and fibroblasts have been shown to have
metabolic abnormalities in multiple studies [46,47,57,58]. Identifying that fibroblast mitochondrial
abnormalities correlate with neuropsychological markers of AD opens up avenues to use fibroblast
metabolic parameters as biomarkers of sAD, and also as a high throughput drug screening model, as
well as potential outcome measures of therapeutic efficacy. Replication of the findings of this study
in larger cohorts and by other groups is needed, however, to consolidate the evidence that fibroblast
metabolic function is a reliable biomarker of sAD.
Our patient cohort were selected at an early stage of sAD to try and reduce group variability.
To understand the use of fibroblast metabolic abnormalities as a biomarker, further work investigating
cohorts of patients with amnestic mild cognitive impairment (MCI), the prodromal stage of sAD,
would be advantageous as well as investigating these parameters in more advanced sAD patients.
Future work could extend the findings of metabolic-neuropsychological correlations by creating
neuronal lineage cells via cellular reprogrammingmethods such as that described byTakahashi et al. [59].
This type of model would allow for direct comparison between human nervous system cells and
human nervous system function in a context where reprogrammed cells would maintain their ageing
phenotype [60].
4. Methods
4.1. Patient Details
Skin biopsies and fibroblast metabolic assessments were performed as part of the MODEL-AD
research study (Yorkshire and Humber Research and Ethics Committee number: 16/YH/0155). Due
to the initial success of fibroblast metabolic assessment, the initial cohort of four controls and four
patients (previously reported in [29]) with sAD was expanded to ten healthy controls (mean age:
65.77 years, SD 14.70 years) and 10 patients with sAD (mean age: 61.33 years, SD 7.19 years).
All patients had been involved in the EU-funded Framework Programme 7 Virtual Physiological
Human: Dementia Research Enabled by IT (VPH-DARE@IT) initiative (http://www.vph-dare.eu/).
A diagnosis of sADwasmade based on clinical criteria [11]. Ethical approval for the neuropsychological
and neuroimaging measures collected was gained from Yorkshire and Humber Regional Ethics
Committee, Reference number: 12/YH/0474. Informed written consent was obtained from each
participant. Investigations were carried out following the rules of the Declaration of Helsinki of 1975
(https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/), revised in 2013.
4.2. Neuropsychological Testing
A battery of tests was devised to detect impaired performance in the cognitive domains most
susceptible to sAD neurodegeneration. This included tests of short- and long-term memory, attention
and executive functioning, language and semantics, and visuoconstructive skills. A detailed description
of each task is provided elsewhere [61]. Most testswere exclusively used as part of the clinical assessment
of patients and controls. Three tests were also included as part of the experimental protocol. Immediate
and delayed recall on the Logical Memory test were used as measures of episodic memory, the
cognitive domain centrally defined by diagnostic criteria for a diagnosis of sAD. The performance on
the Category Fluency test was used as an index of semantic memory, the cognitive domain affected by
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the accumulation of neurofibrillary pathology in the transentorhinal cortex [50]. Finally, the Letter
Fluency test (phonemic fluency) was used as a methodological control, since performance on this task
is often within normal age limits in patients with mild sAD [33,62].
4.3. MRI Acquisition and Processing
An MRI protocol of anatomical scans was acquired on a Philips Ingenia 3 T scanner. Several
acquisitions (including T1-weighted, T2-weighted, FLAIR and diffusion-weighted sequences) were
used for diagnostic purposes. Three-dimensional T1-weighted images (voxel size: 0.94 mm ×
0.94 mm × 1.00 mm; repetition time: 8.2 s; echo delay time: 3.8 s; field of view: 256 mm; matrix
size: 256 × 256 × 170) were also used for the calculation of hippocampal volumes. These were
processed with the Similarity and Truth Estimation for Propagated Segmentations routine [63].
This procedure, available at niftyweb.cs.ucl.ac.uk, allows automated segmentation of the left and
right hippocampus in the brain’s native space using multiple reference templates. Hippocampal
volumes were then quantified using Matlab (version R2014a) and the “get totals” script (http:
//www0.cs.ucl.ac.uk/staff/G.Ridgway/vbm/get_totals.m). Fractional measures were also obtained
dividing hippocampal volumes by the volume of the total intracranial space. The left hippocampal
volume and left hippocampal ratio were chosen as structural markers of AD as evidence suggests the
left hippocampus is affected early in the progression of the disease [64]. Native space maps created to
extract hippocampal volume from MRI images are shown in Supplementary Figure S1. Additional
regions of interest (listed in Table 2) were then defined as binary image masks. Segmented grey matter
maps were registered to the Montreal Neurological Institute space, and mask-constrained volumes
were extracted.
4.4. Tissue Culture
Fibroblasts were cultured as described previously [29]. In brief, all 10 control and all 10 sAD
lines were cultured in EMEM-based media (Corning) incubated at 37 ◦C in a 5% carbon dioxide
atmosphere. Sodium pyruvate (1%) (Sigma Aldrich), non-essential amino acids (1%) (Lonza), penicillin
and streptomycin (1%) (Sigma Aldrich), multi-vitamins (1%) (Lonza), Fetal Bovine Serum (10%)
(Biosera) and 50µg/mL uridine (Sigma Aldrich) were added to the media. All experiments described
were performed on all 20 cell lines. Fibroblasts were plated at a density of 5000 cells per well in a white
96 well plate for ATP assays. For MMP assays fibroblasts were plated at a density of 2500 cells per
well in a black 96 well plate. Each assay was performed on three separate passages of fibroblasts; cells
between passages 5–10 were used. All experiments were performed on passage-matched cells.
4.5. Intracellular ATP levels
Cellular adenosine triphosphate (ATP) levelsweremeasured using theATPlite kit (Perkin Elmer) as
described previously [65]. ATP levels were corrected for cell number by using CyQuant (ThermoFisher)
measurements, as previously described [29]. These values were then normalised to control levels.
4.6. Mitochondrial Membrane Potential
MMP was measured using tetramethlyrhodamine (TMRM) staining of live fibroblasts,
as previously described [29]. Cells were plated in a black 96 well plate, incubated at 37 ◦C for
48 h. TMRM dye was added one hour prior to imaging on an InCell Analyzer 2000 high-content imager
(GE Healthcare).
4.7. Extracellular Lactate Measurement
Extracellular lactate was measured from confluent flasks of fibroblasts using an L-Lactate assay
kit (Abcam ab65331). The assay was performed according to the manufacturer’s instructions.
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4.8. Metabolic Flux Assay
4.8.1. Mito Stress Test
Oxygen consumption rates (OCR) were measured using a 24-well Agilent Seahorse XF analyzer
as described previously [29]. In brief, cells were plated at a density of 65,000 cells per well 48 h prior to
measurement. Three measurements were taken at the basal point: after the addition of oligomycin
(0.5 µM), after the addition of carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) (0.5 µM)
and after the addition of rotenone (1 µM). OCR measurements were normalised to cell count as
described in [29]. Measurements of basal mitochondrial respiration, maximal mitochondrial respiration
and MSRC were also calculated.
4.8.2. Glycolysis Stress Test
Cells were plated in a Seahorse XF24 Cell Culture Microplate (Agilent) at a density of 65,000
cells per well 48 h prior to measurement. The glycolysis stress test standard protocol was used [66].
This is a completely separate assay to the mitochondrial stress test, and allows for the thorough
interrogation of glycolysis via the addition of supplements and inhibitors of the glycolytic pathway.
Three measurements were taken at the basal point: after the addition of glucose (10 µM), after the
addition of oligomycin (1.0 µM) and after the addition of 2-deoxyglucose (50 µM). The glycolysis stress
test can measure several aspects of cellular glycolysis. These include the basal glycolytic rate of the
cell, the maximum level of glycolysis the cell can achieve and the glycolytic reserve which refers to the
difference between maximum level of glycolysis and the basal level of glycolysis. The different aspects
of glycolysis are calculated by measuring the extracellular acidification rate (ECAR). ECAR rates were
normalised to cell count as described above.
4.9. Statistical Analysis
For comparing each neuropsychological, neuroimaging and metabolic functional markers,
a Student’s t-test was used, comparing the means of the control group for each parameter to the disease
group. Statistics were calculated using GraphPad Prism Software (V7.02). Analyses of covariance
were also used for group comparisons including confounding variables. For covariate analysis when
comparing control and disease group greymatter volumes, or when correlating neuropsychological and
neuroimaging sAD markers with fibroblast functional markers, the IBM SPSS Statistics suite (Version
26; https://www.ibm.com/uk-en/products/spss-statistics) was used as this function was not available in
the GraphPad Prism Software. Significance levels were adjusted to account for multiple comparisons.
5. Conclusions
These data highlight how in-depth analysis of mitochondrial and glycolytic function in sAD
fibroblasts identifies metabolic abnormalities that parallel changes seen in neuropsychological features
distinctive of the early stages of sporadic Alzheimer’s disease. This model system could be used
to develop biomarkers useful in early detection as well as in the development of novel therapeutic
approaches for sAD.
Supplementary Materials: The following are available online at http://www.mdpi.com/2075-4426/10/2/32/s1,
Figure S1: Quantification of hippocampal volumes from T1-weighted MRI scans.
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